癫痫持续状态的死亡率、残疾与预后因素:一项全国性人群回顾性队列研究
该研究利用韩国国民健康保险服务(NHIS)数据库联动死亡与残疾登记,纳入2010年1月1日至2018年12月31日新发癫痫持续状态(SE)患者33814例(儿童青少年6818例,成人26996例),评估30天与1年死亡率、神经残疾及预后因素。结果显示30天死亡率为8.5%(儿童1.8%,成人10.2%),1年死亡率为25.1%(儿童4.6%,成人30.3%);10.7%患者新发神经残疾,5-9岁儿童发病率最高(21.3%);难治性癫痫发生率为0.8%。高龄、急性病因及难治性为儿童与成人共同的死亡不良预后因素,男性、低经济状态、无活动性癫痫及合并症为成人额外不良预后因素。
要点
- 新发SE患者30天死亡率为8.5%,1年死亡率为25.1%。
- 10.7%患者新发神经残疾,5-9岁儿童发病率最高(21.3%)。
- 高龄、急性病因及难治性为儿童与成人共同的死亡不良预后因素。
核心结论
- 新发SE与显著的死亡率和残疾相关;成人SE相关死亡率更高,但儿童与青少年更常发生残疾;儿童与成人SE的主要死亡决定因素不同。
研究设计与样本
- 全国性人群回顾性队列研究,使用国民健康保险服务(NHIS)数据库联动全国死亡与残疾登记,纳入2010年1月1日至2018年12月31日新发SE患者33814例(儿童青少年6818例,成人26996例)。
主要发现
- 30天死亡率为8.5%(儿童SE 1.8%,成人SE 10.2%),1年死亡率为25.1%(儿童SE 4.6%,成人SE 30.3%)。
- 10.7%患者新发神经残疾,5-9岁儿童发病率最高(21.3%)。
- 难治性癫痫发生于全部SE的0.8%。
- 高龄、急性病因及难治性为儿童与成人SE死亡的不良预后因素;男性、低经济状态、无活动性癫痫及合并症为成人额外不良预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The outcome of status epilepticus (SE) largely varies depending on clinical characteristics. Risk stratification is necessary for tailoring the aggressiveness of treatment and predicting outcomes of individual patients with SE. In this study, we assessed differences in mortality, neurologic disability, and prognostic factors associated with SE across sociodemographic and clinical characteristics. METHODS: We conducted a nationwide population-based retrospective cohort study using the National Health Insurance Service (NHIS) database linked with the national death and disability registries. SE was identified from admission or emergency department visits using a diagnostic code of G41 from the International Classification of Diseases, 10th Revision. Individuals with new-onset SE that occurred from January 1, 2010, to December 31, 2018, were included. Active epilepsy, refractoriness of SE, potential etiology, and comorbidities were ascertained by diagnostic codes and/or prescription records from the NHIS database as potential prognostic factors. Outcomes included 30-day and 1-year mortality and neurologic disabilities after SE. Prognostic factors for mortality were assessed by the Cox regression hazard model. We performed a subgroup analysis according to age: pediatric SE (age <20 years) and adult SE (age ≥20 years). RESULTS: A total of 33,814 patients with new-onset SE were included (6,818 children/adolescents and 26,996 adults). The 30-day mortality was 8.5% (1.8% in pediatric SE and 10.2% in adult SE), and the 1-year mortality was 25.1% (4.6% in pediatric SE and 30.3% in adult SE). Overall, 10.7% of patients newly acquired neurologic disabilities after SE, with the highest incidence in children aged 5-9 years (21.3%). Intractable epilepsy developed in 0.8% of entire SE. Old age, presence of acute etiology, and refractoriness were poor prognostic factors for mortality in both pediatric and adult SE. Male sex, low economic status, no active epilepsy, and comorbidities were additional factors for a poor prognosis in adults. DISCUSSION: New-onset SE was associated with substantial mortality and disability. Although SE-related mortality was higher in adults, disabilities developed more commonly in children and adolescents. The major determinants of mortality differed between pediatric and adult SE.
引用
- Choi SA, Lee H, Kim K, et al. Mortality, Disability, and Prognostic Factors of Status Epilepticus: A Nationwide Population-Based Retrospective Cohort Study. Neurology. 2022. PMID: 35835559. doi:10.1212/WNL.0000000000200912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。